Parathyroid AdenomasPARAGONNCT07099404
Parathyroid Adenoma Detection With Rubidium-82 Imaging
An observational study of Parathyroid Adenomas and Hyperparathyroidism, Primary, run by Matthieu Pelletier-Galarneau, MD MSc at 2 sites in Canada.
Trial summary
Assess the uptake of rubidium-82 in parathyroid adenomas. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Parathyroid Adenomas, Hyperparathyroidism, Primary
- What is being tested?
- PET/CT imaging with rubidium-82
- Type of treatment
- Injection or infusion
- How many people
- 20 participants
- Where
- 2 sitesCanada
- Study dates
- Nov 2026to Sep 2028
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: 20 participants with a diagnosis of primary parathyroid adenoma who have previously undergone 18F-fluorocholine imaging will be recruited.
Who may be able to join
- Age ≥ 18y
- Ability to undergo imaging logistics
- Ability to provide informed consent
- Biochemical evidence of primary hyperparathyroidism
- Documented parathyroid adenoma on prior 18F-fluorocholine imaging
Who cannot join
- Normocalcemic primary hyperparathyroidism
- Breastfeeding or pregnancy
- Claustrophobia or inability to undergo imaging logistics
- Any other history, condition, therapy, or uncontrolled intercurrent illness, which could in the opinion of the investigator affect compliance with study requirements or which would make the participant unsuitable for this study
Trial locations and contacts
2 sites in 1 country. Contact the study team or a site near you to ask about taking part.
Canada2 sites
Montreal Heart Institute
Montreal, Quebec, H1T 1C8
Montreal Jewish General Hospital
Montreal, Quebec, H3T 1E2
About this study
Official title: Parathyroid Adenoma Detection With Rubidium Chloride Imaging: A Proof-of-Concept Study
Assess the uptake of rubidium-82 in parathyroid adenomas.
Read the detailed description
Parathyroid adenomas demonstrate uptake of rubidium-82 chloride and can be detected with PET imaging.
The investigators aim to describe the uptake pattern of rubidium-82 chloride in parathyroid adenomas as well as compare the uptake pattern of rubidium-82 chloride to that of 18F-fluorocholine in patients with parathyroid adenoma.
- Conditions
- Parathyroid Adenomas, Hyperparathyroidism, Primary
- Being tested
- PET/CT imaging with rubidium-82
- Keywords
- Parathyroid adenomas, Rubidium-82
- Medical subject headings
- Parathyroid Neoplasms, Hyperparathyroidism, Primary
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
PET/CT imaging with rubidium-82Other
Also called Rubidium-82, PET/CT
PET imaging of the neck will be started immediately before infusion of 10 Megabecquerels per kilograms of rubidum-82 over 30 seconds. The acquisition will last 10 minutes. This will be followed by a non-contrast low-dose CT of the neck for localization and attenuation correction.
What is being measured
The primary outcome is the main question the study is designed to answer.
Uptake pattern of rubidium-82 in parathyroid adenomas
Rudibium-82 uptake will be assessed using Maximum Standardized Uptake Value (SUVmax) and target-to-background ratios (TBR). TBR is calculated by dividing a lesion SUVmax by the mean SUV (SUVmean) or the blood pool. Maximum Standardized Uptake Value (SUVmax) and target-to-background (TBR) will be presented as median with interquartile range as well as minimum and maximum values.
Measured: 3 months
Secondary outcomes (1)
Comparison between the uptakes of rubidium-82 and 18F-fluorocholine in patients with parathyroid adenomas
Radioactive tracer uptake will be compared between Rudibium-82 and 18F-Fluorocholine. Uptake will be assessed using Maximum Standardized Uptake Value (SUVmax) and target-to-background ratios (TBR). TBR is calculated by dividing a lesion SUVmax by the mean SUV (SUVmean) or the blood pool. Maximum Standardized Uptake Value (SUVmax) and target-to-background (TBR) will be presented as median with interquartile range as well as minimum and maximum values.
Measured: 3 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted1 Aug 2025
- Study startNov 2026 (estimated)
- Primary completionSep 2027 (estimated)
- Study completionSep 2028 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Parathyroid AdenomasStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case only
- Time perspective
- Prospective
- Enrolment
- 20 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Matthieu Pelletier-Galarneau, MD MSc
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor-investigator, Matthieu Pelletier-Galarneau, MD MSc, Montreal Heart Institute
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07099404
- Sponsor's protocol ID
- MP-33-2025-3547
- Acronym
- PARAGON
- Status last verified
- Oct 2026
- First submitted
- 25 Jul 2025
- Last updated
- 27 Oct 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 27 Oct 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Parathyroid Adenoma Detection With Rubidium Chloride Imaging: A Proof-of-Concept Study
- ClinicalTrials.gov ID
- NCT07099404
- Acronym / sponsor ID
- PARAGON / MP-33-2025-3547
- Conditions
- Parathyroid Adenomas, Hyperparathyroidism, Primary
- Keywords
- Parathyroid adenomas, Rubidium-82
- Study type
- Observational
- Recruitment status
- Enrolling by invitation
- Enrolment
- 20 participants (estimated)
- Lead sponsor
- Matthieu Pelletier-Galarneau, MD MScUniversity, hospital or other
- Study start
- Nov 2026 (estimated)
- Primary completion
- Sep 2027 (estimated)
- Study completion
- Sep 2028 (estimated)
- First posted
- 1 Aug 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Assess the uptake of rubidium-82 in parathyroid adenomas.
Detailed description
Parathyroid adenomas demonstrate uptake of rubidium-82 chloride and can be detected with PET imaging.
The investigators aim to describe the uptake pattern of rubidium-82 chloride in parathyroid adenomas as well as compare the uptake pattern of rubidium-82 chloride to that of 18F-fluorocholine in patients with parathyroid adenoma.
Study design
- Observational model
- Case only
- Time perspective
- Prospective
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- 20 participants with a diagnosis of primary parathyroid adenoma who have previously undergone 18F-fluorocholine imaging will be recruited.
Key inclusion criteria (5 listed)
- Age ≥ 18y
- Ability to undergo imaging logistics
- Ability to provide informed consent
- Biochemical evidence of primary hyperparathyroidism
- Documented parathyroid adenoma on prior 18F-fluorocholine imaging
Key exclusion criteria (4 listed)
- Normocalcemic primary hyperparathyroidism
- Breastfeeding or pregnancy
- Claustrophobia or inability to undergo imaging logistics
- Any other history, condition, therapy, or uncontrolled intercurrent illness, which could in the opinion of the investigator affect compliance with study requirements or which would make the participant unsuitable for this study
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| PET/CT imaging with rubidium-82Also: Rubidium-82, PET/CTPET imaging of the neck will be started immediately before infusion of 10 Megabecquerels per kilograms of rubidum-82 over 30 seconds. The acquisition will last 10 minutes. This will be followed by a non-contrast low-dose CT of the neck for localization and attenuation correction. | Other | – |
Primary outcome
Uptake pattern of rubidium-82 in parathyroid adenomas
Time frame: 3 months
Rudibium-82 uptake will be assessed using Maximum Standardized Uptake Value (SUVmax) and target-to-background ratios (TBR). TBR is calculated by dividing a lesion SUVmax by the mean SUV (SUVmean) or the blood pool. Maximum Standardized Uptake Value (SUVmax) and target-to-background (TBR) will be presented as median with interquartile range as well as minimum and maximum values.
1 secondary outcome
Comparison between the uptakes of rubidium-82 and 18F-fluorocholine in patients with parathyroid adenomas
Time frame: 3 months
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 27 Oct 2026.
- Individual participant dataSharing planned: No
Related trials for Parathyroid Adenomas
RecruitingPhase 2/3
99mTc Sestamibi SPECT/CT vs 18F Fluorocholine PET/CT
Parathyroid Adenoma
RecruitingObservational study
Molecular and Immunohistochemical Profiling of Tumors in Patients With Parathyroid Tumors
Parathyroid Gland Adenoma, Parathyroid Gland Atypical Adenoma
Enrolling by invitation
Comparison of NeuroEXPLORER PET/CT Versus Standard-of-care PET/CT of the Head and Neck Region.
Dementia, Movement Disorders
Not yet recruitingObservational study
Aldosterone Variations in Patients With Primary Hyperparathyroidism After Surgery
Primary Hyperparathyroidism, Primary Hyperparathyroidism Due to Adenoma
Not yet recruiting
WHITE CAP: Intra-operative Parathyroid Tissue Sensor (PTS)-Guided Assessment of Parathyroid Viability and Surgical Decision-Making
Hyperparathyroidism, Primary, Parathyroid Neoplasms
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
The record lists no contact. Use the official record to reach the sponsor.
2 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Parathyroid Adenomas and Hyperparathyroidism, Primary, run by Matthieu Pelletier-Galarneau, MD MSc at 2 sites in Canada.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: enrolling by invitation, as of the sponsor's last update on 27 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 2 sites in Canada. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Uptake pattern of rubidium-82 in parathyroid adenomas (time frame: 3 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 27 Oct 2026; AzTrials last refreshed its copy on 31 Oct 2026.